StrainX Biotech
StrainX Biotech (StrainX Bioworks) harnesses synthetic biology and precision fermentation to create sustainable, high-value biomolecules for food, nutraceuticals, and beauty applications. The company's proprietary precision fermentation platform engineers custom-designed microbial strains that produce biomolecules with superior quality and function at industrial scale, reducing waste, energy consumption, and…
Funding snapshot
About
StrainX Biotech (StrainX Bioworks) harnesses synthetic biology and precision fermentation to create sustainable, high-value biomolecules for food, nutraceuticals, and beauty applications. The company's proprietary precision fermentation platform engineers custom-designed microbial strains that produce biomolecules with superior quality and function at industrial scale, reducing waste, energy consumption, and environmental impact compared to traditional agricultural and manufacturing methods. StrainX delivers three product categories: functional food ingredients providing clean-label alternatives to traditional additives with enhanced taste, texture, and nutrition; nutraceutical health-promoting compounds engineered for optimal bioavailability and efficacy; and innovative active ingredients for skincare and personal care with sustainable sourcing that reduces reliance on animal-derived or synthetic materials. The platform emphasizes resource efficiency with significantly lower water, land, and energy usage, reduced greenhouse gas emissions through fermenter-based production, and closed-loop circular economy systems. StrainX collaborates with partners to develop tailored biomolecules for specific applications across food, beverage, CPG, and D2C brands. Founded in 2023 and headquartered in Bhopal, India, the company has raised approximately $13 million at the Series B stage from investors including Leo Capital, Prime Venture Partners, Good Startup, Sparrow Capital, Sun Icon Ventures, and WindT Angels.
Business model
Genomics > Applied Genomics > Synthetic Biology,
Nutraceuticals Tech > Dietary Supplements > Disease Specific > Diversified,
Biopharma Outsourcing > CDMO > Nutraceuticals
Founders & team highlights
Serial Founder
Team background
Company Wise > Boston Consulting Group,
College Wise > IIT Delhi
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.